Catalog #CP097
RecombiMAb anti-mouse CXCR6 (CD186)
Clone
Cx6MAb-1-CP097
Reactivities
Mouse
Isotype
Mouse IgG2a, κ
(switched from Rat IgG1, κ)
(switched from Rat IgG1, κ)
Product Description
The Cx6MAb-1-CP097 monoclonal antibody is a recombinant, Fc-engineered chimeric version of the original Cx6Mab-1 antibody. The variable domain sequences are identical but the constant region sequences have been switched from Rat IgG1, κ to Mouse IgG2a, κ for use in murine models. Species-matched chimeric antibodies exhibit regulated effector functions—including Fc receptor binding and complement activation—and result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. This antibody has an effector function competent Fc domain allowing for activation of Fcγ receptors (FcγRs) to trigger antibody‑dependent cellular cytotoxicity (ADCC), antibody‑dependent cellular phagocytosis (ADCP), complement‑dependent cytotoxicity (CDC) and opsonization to promote target cell depletion. The mouse IgG2a isotype demonstrates strong effector functions due to potent interaction with mFcγRIV, which is functionally similar to the FcγRIIIa receptor involved in human ADCC. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies.
The Cx6Mab-1 monoclonal antibody reacts with the N-terminal extracellular ligand-binding domain of mouse CXC chemokine receptor 6 (mCXCR6) also known as CD186, BONZO, or STRL33. CXCR6 is expressed on naive CD8+ T cells and a subset of memory CD4+ T cells, natural killer T cells (NKTs), dendritic cells (DCs), pulmonary alveolar macrophages, and innate lymphoid cells (ILCs). The ligand for CXCR6 is C-X-C chemokine CXCL16 that is predominantly expressed in DCs, monocytes, and various other tissue cells, primarily epithelial cells. The CXCR6-CL16 interaction guides immune cell homing (T lymphocyte migration to peripheral tissues) and their activation, expansion, and cytotoxic activity. Retroviruses such as simian immunodeficiency viruses (SIVs), some strains of HIV-2, and macrophage-tropic HIV-1 use CXCR6 as a coreceptor in conjunction with CD4 to enter target cells. In solid tumors, CXCR6 mediates CD8+ T-cell homing to tumor stromal perivascular niches and promotes interactions with CXCL16+ DCs and IL-15 expression for facilitating the growth of T-cells inside the tumor microenvironment. CXCR6 expression is also linked to the activation of Akt/mTOR and ERK/MAPK pathways and other downstream targets responsible for cancer growth and metastasis. CXCR6’s prognostic significance varies among malignancies, but it is regarded as a reliable biomarker to predict the response to anti-PD-1 immunotherapy in various cancers.
The Cx6Mab-1 monoclonal antibody reacts with the N-terminal extracellular ligand-binding domain of mouse CXC chemokine receptor 6 (mCXCR6) also known as CD186, BONZO, or STRL33. CXCR6 is expressed on naive CD8+ T cells and a subset of memory CD4+ T cells, natural killer T cells (NKTs), dendritic cells (DCs), pulmonary alveolar macrophages, and innate lymphoid cells (ILCs). The ligand for CXCR6 is C-X-C chemokine CXCL16 that is predominantly expressed in DCs, monocytes, and various other tissue cells, primarily epithelial cells. The CXCR6-CL16 interaction guides immune cell homing (T lymphocyte migration to peripheral tissues) and their activation, expansion, and cytotoxic activity. Retroviruses such as simian immunodeficiency viruses (SIVs), some strains of HIV-2, and macrophage-tropic HIV-1 use CXCR6 as a coreceptor in conjunction with CD4 to enter target cells. In solid tumors, CXCR6 mediates CD8+ T-cell homing to tumor stromal perivascular niches and promotes interactions with CXCL16+ DCs and IL-15 expression for facilitating the growth of T-cells inside the tumor microenvironment. CXCR6 expression is also linked to the activation of Akt/mTOR and ERK/MAPK pathways and other downstream targets responsible for cancer growth and metastasis. CXCR6’s prognostic significance varies among malignancies, but it is regarded as a reliable biomarker to predict the response to anti-PD-1 immunotherapy in various cancers.
Specifications
| Isotype | Mouse IgG2a, κ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb mouse IgG2a isotype control, unknown specificity |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Immunogen | Synthetic peptide corresponding to the N-terminal extracellular region of mouse CXCR6 (AA 1-19) |
| Reported Applications |
in vivo depletion of CXCR6+ cells Flow cytometry Western blot ELISA |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Aggregation |
<5% Determined by SEC |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from mammalian cell supernatant in an animal-free facility |
| Purification | Protein A |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |